A Clinical Trial of Antiplatelets in Psoriasis

Inclusion Criteria: 1. One of the following: 1. A history of psoriasis as confirmed by a board-certified dermatologist OR 2. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist 2. Age ≥ 18 \& \< 90 years 3. Able and willing to provide written informed consent for the study 4. English-speaking unless a translated informed consent form is approved 5. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment Exclusion Criteria: 1. A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease 2. Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment 3. Uncontrolled hypertension resting systolic blood pressure \> 180 mm Hg or diabetes HbA1c \> 10% 4. Known active cancer receiving treatment 5. Pregnancy 6. Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600) 7. A history of severe bleeding or bleeding disorders 8. Active gastrointestinal ulcer 9. Active pathological bleeding. 10. Chronic kidney disease (CrCl \< 30ml/min) 11. Congestive heart failure 12. Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules 13. History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs 14. Currently breastfeeding 15. Persons of childbearing potential unwilling to use acceptable contraception during the study